The Surging Popularity of GLP-1s By 2024, approximately 4% of Americans were taking a GLP-1 receptor agonist for weight loss, obesity, or type 2 diabetesa staggering 600% increase since 2018
JAMA Ophthalmology studies have provided critical insights through rigorous methodological approaches: Retrospective cohort analyses involving tens of thousands of patients revealed temporal relationships between medication initiation and onset of visual symptoms Case-control studies demonstrated dose-dependent relationships, with higher cumulative exposures correlating with elevated risk profiles Subgroup analyses identified specific patient characteristics that modified risk magnitudes Pharmacovigilance Analysis: Conducted through the FDA Adverse Event Reporting System (FAERS) database has corroborated these findings through real-world evidence
Compounded medications can be tailored to your specific needs and may be better tolerated by your body
This dual-hormone approach is why tirzepatide is often described as a dual agonist. It works on two different pathways to manage blood sugar and appetite
A food-first approach for glutathione support focuses on adequate protein intake (for cysteine, glycine, and glutamic acid), abundant fruits and vegetables (for direct glutathione and vitamin C), and regular intake of cruciferous vegetables (for Nrf2 activation)